Radioisotope and anticancer agent incorporated layered double hydroxide for tumor targeting theranostic nanomedicine

• Published in: Applied clay science 2020-03, Vol.186, p.105454, Article 105454
• Main Authors: Kim, Hyoung-Jun, Lee, Jun Young, Kim, Tae-Hyun, Gwak, Gyeong-Hyeon, Park, Jeong Hoon, Oh, Jae-Min
• Format: Article
• Language: English
• Subjects: Layered double hydroxide; Radioisotope; Single-photon emission computed tomography; Theranosis
• ISSN: 0169-1317; 1872-9053
• DOI: 10.1016/j.clay.2020.105454

Theranostic nanomedicine was successfully prepared using layered double hydroxide (LDH). By means of step-by-step incorporation of an anticancer drug, methotrexate (MTX), and a radioisotope, Co-57, into the interlayer space and lattice of LDH, respectively, theranostic hybrid Nanomedicine could be prepared. X-ray diffractometry, scanning electron microscopy, X-ray adsorption spectroscopy, and Fourier-transform infrared spectroscopy systematically showed that incorporating the Co2+ into the MTX-LDH did not alter the crystalline phase, size, morphology, or intact structure of the hybrid. The labeled Co-57 in MTX-LDH was highly stable in human serum, showing almost 90% retention after 48 h. In vitro cellular uptake of Co-57-labeled MTX-LDH was very high in mouse colon carcinoma CT-26 cells, with ~60 ID% at 4 h. The cytotoxicity assay of MTX-LDH showed high cancer-cell suppression on CT-26 cells. To evaluate the diagnostic ability of Co-57-labeled MTX-LDH, in vivo single-photon emission computed tomography (SPECT) images were investigated on CT-26 xenografted mouse model. The SPECT signal in tumor tissue began to appear within 1 h, and it increased for 3 h. [Display omitted] •Theranostic nanomedicine based on LDH was successfully prepared.•The radioisotope was substituted and drug was intercalated into LDH.•The radioisotope tracer, Co-57, showed rapid contrasting effect in tumor model.•The loaded drug showed high anticancer activity through efficient delivery.